Published in Ann Intern Med on October 01, 1973
Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man. J Clin Invest (1979) 2.50
Role of lipopolysaccharide in virulence of Pseudomonas aeruginosa. Infect Immun (1984) 2.39
Protective immunity induced in mice by immunization with high-molecular-weight polysaccharide from Pseudomonas aeruginosa. Infect Immun (1978) 2.04
Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa. J Clin Invest (1982) 1.97
Functional role of antibody against "core" glycolipid of Enterobacteriaceae. J Clin Invest (1975) 1.80
Evaluation of a new polyvalent Pseudomonas vaccine in respiratory infections. Infect Immun (1979) 1.61
Simple model for the study of Pseudomonas aeruginosa infections in leukopenic mice. Infect Immun (1983) 1.57
Passive protection against Pseudomonas aeruginosa infection in an experimental leukopenic mouse model. Infect Immun (1983) 1.45
Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans. J Clin Invest (1987) 1.33
Neutrophil function in gram-negative rod bacteremia. The interaction between phagocytic cells, infecting organisms, and humoral factors. J Clin Invest (1976) 1.19
Evaluation of type-specific and non-type-specific pseudomonas vaccine for treatment of pseudomonas sepsis during granulocytopenia. Infect Immun (1976) 1.18
Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa. Infect Immun (1994) 1.06
Lung defenses against Pseudomonas aeruginosa in C5-deficient mice with different genetic backgrounds. Infect Immun (1986) 1.01
Immunochemical characterization of high-molecular-weight polysaccharide from Fisher immunotype 3 Pseudomonas aeruginosa. Infect Immun (1984) 0.96
Preparation and preclinical evaluation of a novel liposomal complete-core lipopolysaccharide vaccine. Infect Immun (2000) 0.94
Effect of cyclophosphamide on the immune response to Pseudomonas aeruginosa in mice. Infect Immun (1976) 0.93
Recent developments for Pseudomonas vaccines. Hum Vaccin (2011) 0.91
Vaccines for Pseudomonas aeruginosa: a long and winding road. Expert Rev Vaccines (2014) 0.89
Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06. Infect Immun (1994) 0.87
Role of nonagglutinating antibody in the protracted immunity of vaccinated mice to Pseudomonas aeruginosa infection. Infect Immun (1978) 0.85
Immunoblot analysis of serological response to Pseudomonas aeruginosa septicaemia in man. J Clin Pathol (1986) 0.84
Preparation and characterization of a nontoxic polysaccharide-protein conjugate that induces active immunity and passively protective antibody against Pseudomonas aeruginosa immunotype 1 in mice. Infect Immun (1984) 0.81
Polysaccharide of the slime glycolipoprotein of Pseudomonas aeruginosa. Infect Immun (1981) 0.79
Type-specific indirect hemagglutinating antibody in patients with Pseudomonas aeruginosa Infection. J Clin Microbiol (1978) 0.78
New developments in the treatment of gram-negative bacteremia. West J Med (1986) 0.76
Infectious diseases: annual review of significant publications. Postgrad Med J (1974) 0.75
Nosocomial pneumonia in patients in intensive care units. West J Med (1985) 0.75
Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med (1991) 7.83
Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet (2001) 7.31
Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut (1999) 7.14
Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med (1986) 6.79
Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J (1987) 6.26
Effect of a general practitioner's consulting style on patients' satisfaction: a controlled study. BMJ (1990) 6.15
Infections caused by Mycobacterium avium complex in immunocompromised patients: diagnosis by blood culture and fecal examination, antimicrobial susceptibility tests, and morphological and seroagglutination characteristics. J Clin Microbiol (1985) 5.22
Referral to hospital: perceptions of patients, general practitioners and consultants about necessity and suitability of referral. Fam Pract (1987) 5.11
Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron (1998) 4.92
Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet (1991) 4.76
Mycobacterial infections in AIDS patients, with an emphasis on the Mycobacterium avium complex. Rev Infect Dis (1987) 4.54
Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex. J Immunol (1988) 4.47
Comparison of criteria derived by government and patients for evaluating general practitioner services. BMJ (1989) 4.36
Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality. Am J Med (1981) 4.31
Legionnaires' disease: clinical features of 24 cases. Ann Intern Med (1978) 4.30
Severe candidal infections: clinical perspective, immune defense mechanisms, and current concepts of therapy. Ann Intern Med (1978) 4.15
Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol (1994) 4.08
Treatment of infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med (1985) 4.02
Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis (1985) 4.00
Laboratory diagnosis of Legionnaires' disease. Am Rev Respir Dis (1980) 3.95
Simple method for elimination of aminoglycosides from serum to permit bioassay of other antimicrobial agents. Antimicrob Agents Chemother (1977) 3.91
Aspergillosis complicating neoplastic disease. Am J Med (1973) 3.80
Diagnostic criteria for Walker-Warburg syndrome. Am J Med Genet (1989) 3.74
A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med (1992) 3.65
Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. BMJ (1999) 3.62
Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J Virol (1987) 3.53
An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. CMAJ (2000) 3.45
Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol (1992) 3.41
Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons. Nat Genet (1997) 3.32
Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. J Gen Virol (1987) 3.28
Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors. J Infect Dis (1972) 3.28
Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med (1994) 3.25
Continuous high-grade mycobacterium avium-intracellulare bacteremia in patients with the acquired immune deficiency syndrome. Am J Med (1985) 3.19
Reasons for referral to hospital: extent of agreement between the perceptions of patients, general practitioners and consultants. Fam Pract (1986) 3.14
Comparative recovery of bacteria and yeasts from lysis-centrifugation and a conventional blood culture system. J Clin Microbiol (1983) 3.09
Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods. Antimicrob Agents Chemother (1987) 3.06
Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother (1997) 3.06
A reevaluation of cancer incidence near the Three Mile Island nuclear plant: the collision of evidence and assumptions. Environ Health Perspect (1997) 3.04
Investigation of burnout in a sample of British general practitioners. Br J Gen Pract (1995) 3.03
Hemagglutination typing of Escherichia coli: definition of seven hemagglutination types. J Clin Microbiol (1980) 3.03
Intraorbital wood. Detection by magnetic resonance imaging. Ophthalmology (1990) 2.99
Bacteremia and fungemia complicating neoplastic disease. A study of 364 cases. Am J Med (1977) 2.92
Measuring general practitioner referrals: patient, workload and list size effects. J R Coll Gen Pract (1988) 2.91
Isolation of Legionella pneumophila from hospital shower heads. Ann Intern Med (1981) 2.89
Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol (1999) 2.88
Activity of five aminoglycoside antibiotics in vitro against gram-negative bacilli and Staphylococcus aureus. Antimicrob Agents Chemother (1973) 2.85
The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther (2003) 2.83
Hemolysin and K antigens in relation to serotype and hemagglutination type of Escherichia coli isolated from extraintestinal infections. J Clin Microbiol (1981) 2.82
In vitro studies of piperacilin, a new semisynthetic penicillin. Antimicrob Agents Chemother (1978) 2.82
Legionnaires' disease: report of sixty-five nosocomially acquired cases of review of the literature. Medicine (Baltimore) (1980) 2.81
Bronchoalveolar lavage in the diagnosis of diffuse pulmonary infiltrates in the immunosuppressed host. Ann Intern Med (1984) 2.80
Immunologic diagnosis of Legionnaires' disease: cross-reactions with anaerobic and microaerophilic organisms and infections caused by them. J Infect Dis (1980) 2.76
Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol (1999) 2.73
Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature (1990) 2.72
Species identification of coagulase-negative staphylococcal isolates from blood cultures. J Clin Microbiol (1982) 2.71
Preferences of healthy and ill patients for style of general practitioner care: implications for workload and financial incentives under the new contract. Br J Gen Pract (1991) 2.66
Epstein-Barr virus infection and replication in a human epithelial cell system. Nature (1992) 2.62
Telephone consultations in general practice: an additional or alternative service? Br J Gen Pract (1995) 2.62
Epstein-Barr virus persistence and virus-associated tumours. Lancet (1994) 2.60
Tobramycin (nebramycin factor 6): in vitro activity against Pseudomonas aeruginosa. Appl Microbiol (1971) 2.60
Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med (1993) 2.56
Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex. J Infect Dis (1986) 2.56
Nontuberculous mycobacterial infections: a clinical review. Infection (2004) 2.56
Septicemia due to Aeromonas hydrophila: clinical and immunologic aspects. J Infect Dis (1973) 2.55
Oxidative damage to DNA in diabetes mellitus. Lancet (1996) 2.54
Serologic responses to Pneumocystis carinii antigens in health and disease. J Infect Dis (1990) 2.51
Patients' responses to risk information about the benefits of treating hypertension. Br J Gen Pract (2001) 2.50
Patients' views of priority setting in health care: an interview survey in one practice. BMJ (1995) 2.50
Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man. J Clin Invest (1979) 2.50
Susceptibility of Legionella pneumophila to twenty antimicrobial agents. Antimicrob Agents Chemother (1980) 2.49
Voltage-activated calcium channels that must be phosphorylated to respond to membrane depolarization. Proc Natl Acad Sci U S A (1987) 2.48
Legionnaires' disease: unusual clinical and laboratory features. Ann Intern Med (1980) 2.46
Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. California Collaborative Treatment Group. Ann Intern Med (1990) 2.45
Comparison of methods for assessing in vitro antibiotic synergism against Pseudomonas and Serratia. J Lab Clin Med (1975) 2.41
Opportunistic infection in previously healthy women. Initial manifestations of a community-acquired cellular immunodeficiency. Ann Intern Med (1982) 2.41
From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis (1990) 2.39
Tuberculosis complicating neoplastic disease. A review of 201 cases. Cancer (1974) 2.36
Legionella infections: a review of five years of research. Rev Infect Dis (1983) 2.30
Radioimmunoassay, acetylating radio-enzymatic assay, and microbioassay of gentamicin: a comparative study. J Lab Clin Med (1975) 2.30
Pneumothorax in AIDS. Ann Intern Med (1991) 2.29
Candidiasis: detection by gas-liquid chromatography of D-arabinitol, a fungal metabolite, in human serum. Science (1979) 2.26
Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins. J Virol (1989) 2.23
Nocardia asteroides infection complicating neoplastic disease. Am J Med (1971) 2.23
Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli. Antimicrob Agents Chemother (1980) 2.23
Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene (1998) 2.22
Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med (1993) 2.22
Isolation of a new serotype of legionnaires' disease bacterium. Lancet (1978) 2.21
Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med (1991) 2.20
A short 5' flanking region containing conserved sequences is required for silkworm alanine tRNA gene activity. Proc Natl Acad Sci U S A (1983) 2.19
The prevalence of yeasts in clinical specimens from cancer patients. Am J Clin Pathol (1980) 2.19
Functional conservation of atonal and Math1 in the CNS and PNS. Development (2000) 2.18
Phycomycosis complicating leukemia and lymphoma. Ann Intern Med (1972) 2.17